267 related articles for article (PubMed ID: 16951229)
1. Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome.
Fischer M; Oberthuer A; Brors B; Kahlert Y; Skowron M; Voth H; Warnat P; Ernestus K; Hero B; Berthold F
Clin Cancer Res; 2006 Sep; 12(17):5118-28. PubMed ID: 16951229
[TBL] [Abstract][Full Text] [Related]
2. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
Warnat P; Oberthuer A; Fischer M; Westermann F; Eils R; Brors B
BMC Cancer; 2007 May; 7():89. PubMed ID: 17531100
[TBL] [Abstract][Full Text] [Related]
3. Identification of DEIN, a novel gene with high expression levels in stage IVS neuroblastoma.
Voth H; Oberthuer A; Simon T; Kahlert Y; Berthold F; Fischer M
Mol Cancer Res; 2007 Dec; 5(12):1276-84. PubMed ID: 18171985
[TBL] [Abstract][Full Text] [Related]
4. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification.
Oberthuer A; Berthold F; Warnat P; Hero B; Kahlert Y; Spitz R; Ernestus K; König R; Haas S; Eils R; Schwab M; Brors B; Westermann F; Fischer M
J Clin Oncol; 2006 Nov; 24(31):5070-8. PubMed ID: 17075126
[TBL] [Abstract][Full Text] [Related]
5. MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
[TBL] [Abstract][Full Text] [Related]
6. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
Shimada H; Nakagawa A; Peters J; Wang H; Wakamatsu PK; Lukens JN; Matthay KK; Siegel SE; Seeger RC
Cancer; 2004 Oct; 101(8):1873-81. PubMed ID: 15386308
[TBL] [Abstract][Full Text] [Related]
7. Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q.
McArdle L; McDermott M; Purcell R; Grehan D; O'Meara A; Breatnach F; Catchpoole D; Culhane AC; Jeffery I; Gallagher WM; Stallings RL
Carcinogenesis; 2004 Sep; 25(9):1599-609. PubMed ID: 15090470
[TBL] [Abstract][Full Text] [Related]
8. Translating expression profiling into a clinically feasible test to predict neuroblastoma outcome.
Schramm A; Vandesompele J; Schulte JH; Dreesmann S; Kaderali L; Brors B; Eils R; Speleman F; Eggert A
Clin Cancer Res; 2007 Mar; 13(5):1459-65. PubMed ID: 17332289
[TBL] [Abstract][Full Text] [Related]
9. High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status.
Westermann F; Henrich KO; Wei JS; Lutz W; Fischer M; König R; Wiedemeyer R; Ehemann V; Brors B; Ernestus K; Leuschner I; Benner A; Khan J; Schwab M
Clin Cancer Res; 2007 Aug; 13(16):4695-703. PubMed ID: 17652624
[TBL] [Abstract][Full Text] [Related]
10. Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients.
Henrich KO; Fischer M; Mertens D; Benner A; Wiedemeyer R; Brors B; Oberthuer A; Berthold F; Wei JS; Khan J; Schwab M; Westermann F
Clin Cancer Res; 2006 Jan; 12(1):131-8. PubMed ID: 16397034
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of gene expression-based classification for neuroblastoma.
Oberthuer A; Hero B; Berthold F; Juraeva D; Faldum A; Kahlert Y; Asgharzadeh S; Seeger R; Scaruffi P; Tonini GP; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Vandesompele J; Vermeulen J; Speleman F; Noguera R; Piqueras M; Bénard J; Valent A; Avigad S; Yaniv I; Weber A; Christiansen H; Grundy RG; Schardt K; Schwab M; Eils R; Warnat P; Kaderali L; Simon T; Decarolis B; Theissen J; Westermann F; Brors B; Fischer M
J Clin Oncol; 2010 Jul; 28(21):3506-15. PubMed ID: 20567016
[TBL] [Abstract][Full Text] [Related]
12. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma.
Spitz R; Hero B; Simon T; Berthold F
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3368-73. PubMed ID: 16740759
[TBL] [Abstract][Full Text] [Related]
13. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome.
Oberthuer A; Hero B; Spitz R; Berthold F; Fischer M
Clin Cancer Res; 2004 Jul; 10(13):4307-13. PubMed ID: 15240516
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis.
Yoshihara K; Tajima A; Komata D; Yamamoto T; Kodama S; Fujiwara H; Suzuki M; Onishi Y; Hatae M; Sueyoshi K; Fujiwara H; Kudo Y; Inoue I; Tanaka K
Cancer Sci; 2009 Aug; 100(8):1421-8. PubMed ID: 19486012
[TBL] [Abstract][Full Text] [Related]
15. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature.
De Preter K; Vermeulen J; Brors B; Delattre O; Eggert A; Fischer M; Janoueix-Lerosey I; Lavarino C; Maris JM; Mora J; Nakagawara A; Oberthuer A; Ohira M; Schleiermacher G; Schramm A; Schulte JH; Wang Q; Westermann F; Speleman F; Vandesompele J
Clin Cancer Res; 2010 Mar; 16(5):1532-41. PubMed ID: 20179214
[TBL] [Abstract][Full Text] [Related]
16. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
17. Neuroblastoma in adolescents: the Italian experience.
Conte M; Parodi S; De Bernardi B; Milanaccio C; Mazzocco K; Angelini P; Viscardi E; Di Cataldo A; Luksch R; Haupt R
Cancer; 2006 Mar; 106(6):1409-17. PubMed ID: 16475209
[TBL] [Abstract][Full Text] [Related]
18. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
[TBL] [Abstract][Full Text] [Related]
19. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
[TBL] [Abstract][Full Text] [Related]
20. GABAergic system gene expression predicts clinical outcome in patients with neuroblastoma.
Roberts SS; Mori M; Pattee P; Lapidus J; Mathews R; O'Malley JP; Hsieh YC; Turner MA; Wang Z; Tian Q; Rodland MJ; Reynolds CP; Seeger RC; Nagalla SR
J Clin Oncol; 2004 Oct; 22(20):4127-34. PubMed ID: 15483022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]